A pharmaceutical dosage form is an entity that is administered to patients so that they receive an effective dose of an active pharmaceutical ingredient (API). The proper design and formulation of a transdermal dosage form require a thorough understanding of the physiological factors affecting percutaneous penetration and physicochemical characteristics of the API, as well as that of the pharmaceutical exipients that are used during formulation. The API and pharmaceutical excipients must be compatible with one another to produce a formulation that is stable, efficacious, attractive, easy to administer, and safe (Mahato, 2007:11). Amongst others, the physicochemical properties indicate the suitability of the type of dosage form, as well as any potential problems associated with instability, poor permeation and the target site to be reached (Wells & Aulton, 2002:337). Therefore, when developing new or improved dosage forms, it is of utmost importance to evaluate the factors influencing design and formulation to provide the best possible dosage form and formulation for the API in question. Delivery of an API through the skin has long been a promising concept due to its large surface area, ease of access, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the therapy. This is true whether a local or systemic pharmacological effect is desired (Aukunuru et al., 2007:856). However, most APIs are administered orally as this route is considered to be the simplest, most convenient and safest route of API administration. Since ibuprofen is highly metabolised in the liver and gastrointestinal tract, oral administration thereof results in decreased bioavailability. Furthermore, it also causes gastric mucosal damage, bleeding and ulceration. Another obstacle associated with oral API delivery is that some APIs require continuous delivery which is difficult to achieve (Bouwstra et al., 2003:3). Therefore, there is significant interest to develop topical dosage forms for ibuprofen to avoid side effects associated with oral delivery and to provide relatively consistent API levels at the application site for prolonged periods (Rhee et al., 2003:14). The aim of this study was to determine the influence of selected formulation factors on the transdermal delivery of ibuprofen. In order to achieve this aim, the physicochemical properties of ibuprofen had to be evaluated. The aqueous solubility, pH-solubility profile, octanol-water partition coefficient (log P-value) and octanol-buffer distribution coefficient (log D-values, pH 5 and 7.4) of ibuprofen were determined. According to Naik et al., (2000:319) the ideal aqueous solubility of APIs for transdermal delivery should be more than 1 mg.ml-1. However, results showed that ibuprofen depicted an aqueous solubility of 0.096 mg.ml-1 ± 25.483, which indicated poor water solubility and would therefore be rendered less favourable for transdermal delivery if only considering the aqueous solubility. The pH-solubility profile depicted that ibuprofen was less soluble at low pH-values and more soluble at higher pH-values. Previous research indicated that the ideal log Pvalues for transdermal API permeation of non steroid anti-inflammatory drugs (NSAIDs) are between 2 and 3 (Swart et al., 2005:72). Results obtained during this study indicated a log P-value of 4.238 for ibuprofen. This value was not included in the ideal range, which is an indication that the lipophilic/hydrophilic properties are not ideal, and this might therefore; contribute to poor ibuprofen penetration through the skin. Furthermore, the obtained log D-values at pH 5 and 7.4 were 3.105 and 0.386, respectively. Therefore, it would be expected that ibuprofen incorporated into a formulation prepared at a pH of 5 would more readily permeate the skin compared to ibuprofen incorporated into a formulation prepared at a pH of 7.4. A gel, an emulgel and a Pheroid™ emulgel were formulated at pH 5 and 7.4, in order to examine which dosage form formulated at which pH would deliver enhanced transdermal delivery. Obtained diffusion results of the different semi-solid formulations were furthermore compared to a South African marketed commercial product (Nurofen® gel) in order to establish if a comparable formulation could be obtained. An artificial membrane was used to conduct the membrane permeation studies over a period of 6 h, in order to determine whether ibuprofen was in fact released from the formulations through the membrane. Skin permeation studies were conducted using Franz diffusion cells over a period of 12 h where samples were withdrawn at specified time intervals. All the formulations exhibited an increase in the average cumulative amount of ibuprofen released from the formulations and that permeated the membrane when compared to Nurofen® gel. This increase was statistically significant (p<0.05) for the gel, emulgel and Pheroid™ emulgel at pH 7.4. The gel at pH 7.4 exhibited the highest cumulative amount of ibuprofen that permeated the membrane. Preparations formulated at a pH of 5, did not differ significantly from Nurofen® when the average cumulative amount of ibuprofen that permeated the membrane were compared. The following rank order for the average cumulative amount released from the formulations could be established: Gel (pH 7.4) >>>> Pheroid™ emulgel (pH 7.4) > Emulgel (pH 7.4) >>> Gel (pH 5)> Pheroid™ emulgel (pH 5) ≈ Emulgel (pH 5) > Nurofen® gel. On the other hand, all the formulations exhibited an increase in the average cumulative amount of ibuprofen that permeated the skin when compared to Nurofen® gel. This increase was statistically significant (p < 0.05) for the gel, emulgel and Pheroid™ emulgel at pH 5, as well as the emulgel and Pheroid™ emulgel at pH 7.4. The emulgel at pH 5 exhibited the highest cumulative amount of ibuprofen that permeated the skin. The following rank order for the average cumulative amount released from the formulations and that permeated the skin could be established: Emulgel (pH 5) >> Pheroid™ emulgel (pH 5) > Gel (pH 5) > Emulgel (pH 7.4)> Pheroid™ emulgel (pH 7.4) ≈ Emulgel (pH 7.4) >> Nurofen® gel > Gel (pH 7.4). From this rank order it was clear that a trend was followed where the pH of formulation also played a role in ibuprofen permeation. All the formulations exhibited a higher release rate and flux when compared to Nurofen® gel. This was statistically significant for the emulgel, gel and Pheroid™ emulgel at pH 7.4. The gel at pH 7.4 exhibited the highest release rate and flux. This was observed for the membrane and skin permeation studies. All the formulations (including Nurofen® gel) presented a correlation coefficient (r2) of 0.972 – 0.995 for membrane permeation studies, and 0.950 – 0.978 for skin permeation studies; indicating that the release of ibuprofen from each of the formulations could be described by the Higuchi model. Furthermore, all the formulations exhibited a prolonged lag time compared to Nurofen® gel which indicated that the ibuprofen was retained for a longer time by the base. This was statistically significant (p < 0.05) for the emulgel at pH 7.4, the gel and Pheroid™ emulgel at pH 5. The gel at pH 7.4 exhibited a lag time closest to that of Nurofen® gel and this difference could not be classified as statistically significant (p > 0.286). This was observed for the membrane and skin permeation studies. Nurofen® gel exhibited the highest ibuprofen concentration in the stratum corneum as well as in the epidermis followed by the gel at pH 7.4. However, results obtained for all the formulations indicated that topical as well as transdermal delivery of ibuprofen was achieved. The pH of a formulation plays an important role with respect to API permeation. Ibuprofen is reported to have a pKa value 4.4 (Dollery, 1999:I1); and by application of the Henderson-Hasselbach equation, at pH 5, 20.08% of ibuprofen will be present in its unionised form and at pH 7.4, 0.1% ibuprofen will exist in its unionised form. Since the unionised form of APIs is more lipid soluble than the ionised form, unionised forms of APIs permeate more readily across the lipid membranes (Surber & Smith, 2000:27). Therefore, it would be expected that ibuprofen formulated at pH 5 would be more permeable than formulations at pH 7.4. However, this did not correspond to the results (membrane studies) obtained in this study. It may be attributed to the solubility of ibuprofen in the different formulations. According to the pH-solubility profile of ibuprofen obtained in this study, it was more soluble at pH 7.4 than at pH 5. This was due to the fact that ibuprofen is a weak acidic compound, and for every 3 units away from the pKa-value, the solubility changes 10-fold (Mahato, 2007:14). However, with regard to the skin permeation studies, enhanced permeation was obtained with the formulations prepared at pH 5. This was in accordance with Corrigan et al., (2003:148) who stated that NSAIDs are less soluble and more permeable at low pH values, and more soluble and less permeable at high pH values. This was most probably due to the fact that unionised species, although possessing a lower aqueous solubility than the ionised species, resulted in enhanced skin permeation due to being more lipid-soluble. Finally, stability tests on the different semi-solid formulations for a period of three months at different temperature and humidity conditions were conducted to determine product stability. The formulations were stored at 25 °C/60% RH (relative humidity), 30 °C/60% RH and 40 °C/75% RH. Stability tests included: mass variation, pH, zeta potential, droplet size, visual appearance, assay, and viscosity. No significant change was observed for mass variation, pH, zeta potential and droplet size over the three months for any of the different formulations stored at the different storage conditions. In addition, no significant change in colour was observed for the gel and emulgel formulations at pH 5 and 7.4 over the three months at all the storage conditions. However, it was observed that the formulations containing Pheroid™ showed a drastic change in colour at all the storage conditions. This might have been due to oxidation of certain components present in the Pheroid™ system. Consequently, further investigation is necessary to find the cause of the discolouration and a method to prevent it. The gel formulated at pH 5 depicted the formation of crystals. This might have been due to the fact that the solubility of ibuprofen was exceeded, leading to it precipitating from the formulation. A possible contributing factor to the varying assay values obtained during the study might have been due to non-homogenous sample withdrawal. On the other hand, no significant change was observed for the emulgel and Pheroid™ emulgel formulated at pH 5 and 7.4. The emulgel and Pheroid™ emulgel formulated at pH 5 depicted relative instability (according to the International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use, ICH) only at 40 °C/75% RH with a change in ibuprofen content of more than 5% (6.78 and 6.46%, respectively). The gel, emulgel and Pheroid™ emulgel at pH 7.4 exhibited the least variation in ibuprofen concentration at all of the storage conditions. This might indicate that the pH at which a semi-solid formulation is produced will have a direct influence on the stability of the product. No significant changes in viscosity (%RSD < 5) was observed for the gel and emulgel formulated at pH 7.4 and stored at 25 °C/60% RH. The remaining formulations at all of the specified storage conditions exhibited a significant change in viscosity (%RSD > 5) with a decrease in viscosity being more pronounced at the higher temperature and humidity storage conditions. A possible contributing factor to the change in viscosity over three months at the specified storage conditions might have been due to the use of Pluronic® F-127 (viscosity enhancer). This viscosity enhancer possesses a melting point of approximately 56 °C (BAST Corporation. s.a). The problem with this might have been the temperature (70 °C) at which the formulations were prepared. The higher preparation temperature might have caused the Pluronic® F-127 to degrade, thereby losing its ability to function appropriately. A balance must be maintained between optimum solubility and maximum stability (Pefile & Smith, 1997:148). Despite the lower skin permeation of the gel formulated at pH 7.4, this formulation performed the best, as it was considered stable (least variation during the 3 month stability test) and the obtained tape stripping results showed that this formulation depicted the highest ibuprofen concentrations in the stratum corneum and epidermis. Thus, topical as well as transdermal delivery were obtained. / Thesis (MSc (Pharmaceutics))--North-West University, Potchefstroom Campus, 2013.

Emulsions are widely used as topical formulations in the pharmaceutical and cosmetic industry. They are thermodynamically unstable and require emulsifiers to stabilize them physically. A literature survey has revealed that emulsifiers could have an effect on topical delivery. Therefore, the overall aim of this research project was to investigate and to understand the various effects of biopolymers, chosen for this study as emulsifiers, on the release and the topical delivery of an active ingredient from emulsion-based delivery systems. Emulsions were stabilized by either whey protein alone or in combination with chitosan or carrageenan. Salicylic acid was chosen as a model drug. Furthermore, the emulsions were prepared at three different pH values (pH 4, 5 and 6) in order to introduce different charges to the polymeric emulsifiers and subsequently determine the effect of pH on release as well as on dermal and transdermal delivery. Emulsion characteristics, such as droplet size, zeta potential, viscosity and stability against creaming and coalescence were ascertained. In addition, turbidity was determined to evaluate the degree of insoluble complex formation in the aqueous phase of the emulsions. A high pressure liquid chromatographic (HPLC) method was validated for the quantitative determination of salicylic acid in the release, skin and transdermal perfusate samples. Nine emulsions were formulated, utilizing the layer-by-layer (LbL) self-assembly technique, from which the release of salicylic acid was determined. These release studies were conducted, utilizing nitrocellulose membranes (0.2 μm pore size) with the use of Franz-type diffusion cells in four replicates per formulation over a time period of 8 hours. Based on the emulsion characterization and release data, six formulations, including the oil solution, were chosen to determine dermal and transdermal delivery of salicylic acid. During the diffusion studies, the effect of different pH (whey protein pH 4.00, 5.00 and 6.00), different polymers and different polymer combinations were investigated. These diffusion studies were conducted with the use of dermatomed (thickness ~400 μm), human abdominal skin and Franz-type diffusion cells over a period of 24 hours. The characterization of the emulsions revealed no significant differences in the droplet size and viscosity between the various formulations. All emulsions showed stability towards coalescence over a time period of 7 days; however, not all the emulsions showed stability towards creaming and flocculation. The results of the release studies indicated that an increase in emulsion droplet charge could have a negative effect on the release of salicylic acid from these formulations. In contrast, positively charged emulsion droplets could enhance the dermal and transdermal delivery of salicylic acid from emulsions. It was hypothesized that electrostatic complex formation between the emulsifier and salicylic acid could affect the release, whereas electrostatic interaction between emulsion droplets and skin could influence dermal/transdermal delivery of the active. Furthermore, the degree of ionization of salicylic acid played an important role in the dermal and transdermal delivery of salicylic acid from the various emulsions. / MSc (Pharmaceutics), North-West University, Potchefstroom Campus, 2014

In pharmaceutical sciences, topical delivery is a transport process of an active pharmaceutical ingredient (API) from a formulated dosage form to the target site of action. For most topical delivery systems, the skin surface, or the specific skin layers, such as the outermost layer of the stratum corneum, the lipids amid the corneocytes within the stratum corneum, the corneocytes themselves, the epidermis, dermis, Langerhans cells, Merckle cells or the appendageal structures can be the target delivery location. When an API is delivered to the skin, it has to firstly diffuse from the formulation in which it is applied, to the skin surface. From there the API may partition into the stratum corneum, permeate across the stratum corneum and partition into the viable epidermis, from where it may partition further into the dermis and permeate across the dermis into the bloodstream (Wiechers, 2008:1-3, 7). With respect to the barrier function of the skin, the intercellular spaces within the stratum corneum contain lipids and its main purpose is to operate as a barrier to water-loss and to provide an imperative diffusional barrier to the absorption of APIs. This resistance is comprised of a complex interaction of lipids that creates a hydrophilic and lipophilic penetration pathway. The fundamental aspect underlying the impermeability of the skin, therefore, is the lipophilic nature of the stratum corneum (Bouwstra et al., 2003:4; Franz & Lehman, 2000:25; Walker & Smith, 1996:296). A common approach for the promotion of poorly penetrating APIs in transdermal delivery is the incorporation of chemical penetration enhancers in delivery systems, in order to promote the partitioning of an API into the stratum corneum. These chemicals are also referred to as accelerants, promoters and absorption promoters. Penetration enhancers are added to topical formulations and usually also partition into the stratum corneum, where they temporarily and reversibly disrupt its fundamental diffusional barrier properties, hence facilitating the absorption of an API through the skin (Büyüktimkin et al., 1997:358-359; Sinha & Kaur, 2000:1131; Walker & Smith, 1996:296). The mechanisms for the enhancement of diffusion of the API should therefore increase the solubility and partitioning of the drug from the formulation into the skin. It should further increase the solubility of the API within the skin and promote its permeability and diffusion coefficient (Rajadhyaksha et al., 1997:489). Fatty acids are recognised to effectively enhance the penetration of transdermally delivered hydrophilic and lipophilic APIs. Many penetration enhancers contain saturated and unsaturated hydrocarbon chains, and a popular fatty acid that has been used in this regard is oleic acid (Williams & Barry, 2004:609-610). It is believed that fatty acids disrupt the lipid organisation of the intercellular lipids within the stratum corneum to cause fluidisation of these bilayers, making the stratum corneum more permeable to APIs. Excipients with polar (hydrophilic) head groups and long hydrophobic chains i.e. fatty acids, can penetrate into the intercellular lipids of the stratum corneum and disrupt these endogenous lipid components, thereby increasing diffusion of an API within the skin (Barry, 2006:9-10; Hadgraft & Finnin, 2006:367-368; Kanikkannan et al., 2006:18; Williams & Barry, 2004:610). Natural oils are widely used in topical formulations and were an obvious choice in this study. Oils are liquids at room temperature, whereas fats are in solid form. They are relatively easy to obtain from both plants and animals. The main constituents of fats and oils are triglycerides comprising of fatty acids and a glycerol. Oils control the evaporation of moisture from the skin, spread easily and evenly and are partly metabolised in the skin to release valuable fatty acids (Fang et al., 2004:170,173; Lautenschläger, 2004:46; Mitsui, 1997:121-122). The focus of this study was not formulation per se, but included the formulation of avocado-, grapeseed-, emu-, crocodile, olive and coconut oil into semisolid emulgel- and two foam formulations. This was done in order to investigate the penetration enhancing properties of their fatty acid content on flurbiprofen which was chosen as the marker API. The emulgels containing the natural oils were compared to the same emulgel formulation containing liquid paraffin, and a hydrogel without the inclusion of an oil. Six natural oils were analysed by gas chromatography (GC) in order to quantify their fatty acid compositions, whilst also providing qualitative information by indicating the retention times of the materials with an alkyl chain composition (Mitsui, 1997:260). Data obtained with the GC indicated that olive- (76%), avocado- (68%), emu- (46%) and crocodile oil (40%) presented with high levels of oleic acid, also known as a mono-unsaturated fatty acid (MUFA). Lower levels of oleic acid were observed within grapeseed- (27%) and coconut oil (8%). The only oil demonstrating high levels of the poly-unsaturated fatty acid (PUFA), linoleic acid, was grapeseed oil (61%), whereas the remainder of the oils showed levels below 24%. Contrary, coconut oil seemed to have been the only oil high in saturated fatty acids (SFAs) and consisted of a lauric acid content of 52% and medium levels of myristic acid (21%). Average levels of palmitic acid (SFA) were found in crocodile- (21%) and in emu oil (21%), both of animal origin, whereas avocado-, grapeseed-, olive- and coconut oils from plants presented with levels below 15%. Stearic acid was also present in levels below 10% in all of these oils, with the oils of animal origin portraying the highest values. A method was developed and validated to determine the concentration of the marker flurbiprofen after diffusion from the formulations into the skin, as well as concentrations of the marker that diffused through the skin, by means of high performance liquid chromatography (HPLC). Franz cell membrane diffusion studies were conducted prior to the skin diffusion studies in order to verify the actual release of the marker from the semisolid formulations. Skin diffusion experiments were performed using dermatomed excised, human skin to which the six emulgel formulations, containing the natural oils, were applied. A comparative study was performed utilising liquid paraffin and a hydrogel, in order to compare the diffusion of the marker, flurbiprofen, into and through the skin. The two oil emulgel formulations that had indicated the best flux values were subsequently formulated into foam preparations in order to compare the penetration enhancement properties on flurbiprofen of these two oils in a foam preparation, to those in the equivalent emulgels. The data generated for all ten the formulations were compared, and the formulations that yielded the best results with regards to median flux values and the flurbiprofen concentrations within the stratum corneum-epidermis and epidermis-dermis, were identified. Application of the liquid paraffin emulgel (21.29 μg/ml) depicted the highest average concentration of the diffused lipophilic flurbiprofen within the stratum corneum-epidermis, followed by the olive oil foam (21.47 μg/ml), olive oil emulgel (17.82 μg/ml) and grapeseed oil emulgel (17.78 μg/ml). Very similar concentrations for the marker were demonstrated by the hydrogel (16.73 μg/ml) and crocodile oil emulgel (14.89 μg/ml), whereas a lower concentration was shown for coconut oil emulgel (7.18 μg/ml). The remainder of the formulations yielded concentrations below 3%, i.e. the avocado oil emulgel (2.72 μg/ml), the coconut oil foam (1.57 μg/ml) and finally the emu oil emulgel (1.25 μg/ml). The penetration of the marker, flurbiprofen, being trapped within the skin seemed to have been enhanced more by the oleic acid (UFA) containing emulgels and foam, especially. This was followed by oils containing high linoleic acid values, which indicated that the more kinked shaped the fatty acids, the more difficult it became to insert themselves within the lipid structures of the stratum corneum, with a resulting accumulation of the marker (Fang et al., 2003:318-319). It therefore seemed that those oils that predominantly consisted of unsaturated fatty acids (UFAs) (grapeseed-, crocodile- and olive oils) seemed to have increased the concentration of the diffused marker more significantly than those oils containing an almost even combination of MUFAs and PUFAs (avocado oil), or those mainly consisting of SFAs (coconut oil). Average concentrations of the diffused flurbiprofen found in the epidermis-dermis region of the skin for all of the formulations demonstrated low concentrations, ranging between 0.97 - 5.39 μg/ml, with the exception of the emu oil emulgel that presented with a higher concentration of 16.15 μg/ml. The reason for the high accumulation of the marker might have been as a result of epidermal proliferation, with subsequent accumulation of the marker within the epidermis-dermis due to high oleic- and linoleic acid values, as well as small amounts of palmitoleic acid present within this oil (Katsuta et al., 2005:1011). The resistance of the epidermis-dermis region to the general permeation of flurbiprofen might have been caused by its lipophilic nature, resulting in a reduced solubility within the hydrophilic environment of this region (Hadgraft, 1999:5). Median results from the skin diffusion studies demonstrated that the hydrogel (23.79 μg/cm2.h) had the highest flux, followed by the olive oil- (17.99 μg/cm2.h), liquid paraffin- (15.70 μg/cm2.h), coconut oil- (13.16 μg/cm2.h), grapeseed oil- (11.85 μg/cm2.h), avocado oil- (8.31 μg/cm2.h), crocodile oil- (6.68 μg/cm2.h) and emu oil emulgels (4.41 μg/cm2.h). The fact that the hydrogel presented a higher flux value for the marker could have been as a result of its high water content that had caused hydration of the skin. Hydration opens up the dense lipid structures inside of the stratum corneum, due to swelling of the corneocytes, with a subsequent increase in the marker‘s flux (Benson, 2005:28; Ranade & Hollinger, 2004:213). The high flux value of flurbiprofen with the liquid paraffin emulgel might also have resulted from the fact that it occluded the skin, which increased the hydration of the stratum corneum, with a subsequent increase in the flux (Mitsui, 1997:124; Thomas & Finnin, 2004:699). Results from the skin diffusion studies could be explained by the fact that the fatty acids differ in their hydrocarbon chain by (1) the length of the chain, and (2) the position- and number of the double bonds (Babu et al., 2006:144). It is suggested that fatty acids with hydrocarbon (lipophilic) chains between C12 to C14 (also present within coconut oil) have an optimal balance of the partition coefficient and its affinity for the skin (Ogiso & Shintani, 1990:1067). It appears as though the branched UFAs, especially oleic acid, present in high quantities in olive oil, were more powerful enhancers of the diffusion of the marker, flurbiprofen (Chi et al., 1995:270). Foam formulations were manufactured with the olive- and coconut oil emulgels that had demonstrated the best median flux values of flurbiprofen from the natural oil emulgel formulations. These formulated foams, however, did not significantly increased flux values for flurbiprofen through the skin, but only achieved values of 5.56 μg/cm2.h for the olive oil foam and 4.36 μg/cm2.h for the coconut oil foam formulations. The low flux values could have been attributed to the nature of the formulation itself, which was filled with trapped air that could have resulted in the formulation not making optimal direct contact with the available skin surface. Throughout this study, it became evident that olive oil, predominantly consisting of oleic acid (UFA), was most effective in enhancing the flux of the lipophilic marker, flurbiprofen, through the skin, closely followed by coconut oil consisting of SFAs, with lauric- and myristic acid as its main constituents. Better enhancement effects were observed with those oils containing high amounts of oleic acid (MUFA), than oils consisting of almost equal amounts of both PUFAs and MUFAs (avocado-, emu- and crocodile oil), or oils mainly consisting of PUFAs (grapeseed oil) as its main components, but their effect was not more significant than the oil containing SFAs (coconut oil) as its key components. / Thesis (MSc (Pharmaceutics))--North-West University, Potchefstroom Campus, 2013.

A pharmaceutical dosage form is an entity that is administered to patients so that they receive an effective dose of an active pharmaceutical ingredient (API). The proper design and formulation of a transdermal dosage form require a thorough understanding of the physiological factors affecting percutaneous penetration and physicochemical characteristics of the API, as well as that of the pharmaceutical exipients that are used during formulation. The API and pharmaceutical excipients must be compatible with one another to produce a formulation that is stable, efficacious, attractive, easy to administer, and safe (Mahato, 2007:11). Amongst others, the physicochemical properties indicate the suitability of the type of dosage form, as well as any potential problems associated with instability, poor permeation and the target site to be reached (Wells & Aulton, 2002:337). Therefore, when developing new or improved dosage forms, it is of utmost importance to evaluate the factors influencing design and formulation to provide the best possible dosage form and formulation for the API in question. Delivery of an API through the skin has long been a promising concept due to its large surface area, ease of access, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the therapy. This is true whether a local or systemic pharmacological effect is desired (Aukunuru et al., 2007:856). However, most APIs are administered orally as this route is considered to be the simplest, most convenient and safest route of API administration. Since ibuprofen is highly metabolised in the liver and gastrointestinal tract, oral administration thereof results in decreased bioavailability. Furthermore, it also causes gastric mucosal damage, bleeding and ulceration. Another obstacle associated with oral API delivery is that some APIs require continuous delivery which is difficult to achieve (Bouwstra et al., 2003:3). Therefore, there is significant interest to develop topical dosage forms for ibuprofen to avoid side effects associated with oral delivery and to provide relatively consistent API levels at the application site for prolonged periods (Rhee et al., 2003:14). The aim of this study was to determine the influence of selected formulation factors on the transdermal delivery of ibuprofen. In order to achieve this aim, the physicochemical properties of ibuprofen had to be evaluated. The aqueous solubility, pH-solubility profile, octanol-water partition coefficient (log P-value) and octanol-buffer distribution coefficient (log D-values, pH 5 and 7.4) of ibuprofen were determined. According to Naik et al., (2000:319) the ideal aqueous solubility of APIs for transdermal delivery should be more than 1 mg.ml-1. However, results showed that ibuprofen depicted an aqueous solubility of 0.096 mg.ml-1 ± 25.483, which indicated poor water solubility and would therefore be rendered less favourable for transdermal delivery if only considering the aqueous solubility. The pH-solubility profile depicted that ibuprofen was less soluble at low pH-values and more soluble at higher pH-values. Previous research indicated that the ideal log Pvalues for transdermal API permeation of non steroid anti-inflammatory drugs (NSAIDs) are between 2 and 3 (Swart et al., 2005:72). Results obtained during this study indicated a log P-value of 4.238 for ibuprofen. This value was not included in the ideal range, which is an indication that the lipophilic/hydrophilic properties are not ideal, and this might therefore; contribute to poor ibuprofen penetration through the skin. Furthermore, the obtained log D-values at pH 5 and 7.4 were 3.105 and 0.386, respectively. Therefore, it would be expected that ibuprofen incorporated into a formulation prepared at a pH of 5 would more readily permeate the skin compared to ibuprofen incorporated into a formulation prepared at a pH of 7.4. A gel, an emulgel and a Pheroid™ emulgel were formulated at pH 5 and 7.4, in order to examine which dosage form formulated at which pH would deliver enhanced transdermal delivery. Obtained diffusion results of the different semi-solid formulations were furthermore compared to a South African marketed commercial product (Nurofen® gel) in order to establish if a comparable formulation could be obtained. An artificial membrane was used to conduct the membrane permeation studies over a period of 6 h, in order to determine whether ibuprofen was in fact released from the formulations through the membrane. Skin permeation studies were conducted using Franz diffusion cells over a period of 12 h where samples were withdrawn at specified time intervals. All the formulations exhibited an increase in the average cumulative amount of ibuprofen released from the formulations and that permeated the membrane when compared to Nurofen® gel. This increase was statistically significant (p<0.05) for the gel, emulgel and Pheroid™ emulgel at pH 7.4. The gel at pH 7.4 exhibited the highest cumulative amount of ibuprofen that permeated the membrane. Preparations formulated at a pH of 5, did not differ significantly from Nurofen® when the average cumulative amount of ibuprofen that permeated the membrane were compared. The following rank order for the average cumulative amount released from the formulations could be established: Gel (pH 7.4) >>>> Pheroid™ emulgel (pH 7.4) > Emulgel (pH 7.4) >>> Gel (pH 5)> Pheroid™ emulgel (pH 5) ≈ Emulgel (pH 5) > Nurofen® gel. On the other hand, all the formulations exhibited an increase in the average cumulative amount of ibuprofen that permeated the skin when compared to Nurofen® gel. This increase was statistically significant (p < 0.05) for the gel, emulgel and Pheroid™ emulgel at pH 5, as well as the emulgel and Pheroid™ emulgel at pH 7.4. The emulgel at pH 5 exhibited the highest cumulative amount of ibuprofen that permeated the skin. The following rank order for the average cumulative amount released from the formulations and that permeated the skin could be established: Emulgel (pH 5) >> Pheroid™ emulgel (pH 5) > Gel (pH 5) > Emulgel (pH 7.4)> Pheroid™ emulgel (pH 7.4) ≈ Emulgel (pH 7.4) >> Nurofen® gel > Gel (pH 7.4). From this rank order it was clear that a trend was followed where the pH of formulation also played a role in ibuprofen permeation. All the formulations exhibited a higher release rate and flux when compared to Nurofen® gel. This was statistically significant for the emulgel, gel and Pheroid™ emulgel at pH 7.4. The gel at pH 7.4 exhibited the highest release rate and flux. This was observed for the membrane and skin permeation studies. All the formulations (including Nurofen® gel) presented a correlation coefficient (r2) of 0.972 – 0.995 for membrane permeation studies, and 0.950 – 0.978 for skin permeation studies; indicating that the release of ibuprofen from each of the formulations could be described by the Higuchi model. Furthermore, all the formulations exhibited a prolonged lag time compared to Nurofen® gel which indicated that the ibuprofen was retained for a longer time by the base. This was statistically significant (p < 0.05) for the emulgel at pH 7.4, the gel and Pheroid™ emulgel at pH 5. The gel at pH 7.4 exhibited a lag time closest to that of Nurofen® gel and this difference could not be classified as statistically significant (p > 0.286). This was observed for the membrane and skin permeation studies. Nurofen® gel exhibited the highest ibuprofen concentration in the stratum corneum as well as in the epidermis followed by the gel at pH 7.4. However, results obtained for all the formulations indicated that topical as well as transdermal delivery of ibuprofen was achieved. The pH of a formulation plays an important role with respect to API permeation. Ibuprofen is reported to have a pKa value 4.4 (Dollery, 1999:I1); and by application of the Henderson-Hasselbach equation, at pH 5, 20.08% of ibuprofen will be present in its unionised form and at pH 7.4, 0.1% ibuprofen will exist in its unionised form. Since the unionised form of APIs is more lipid soluble than the ionised form, unionised forms of APIs permeate more readily across the lipid membranes (Surber & Smith, 2000:27). Therefore, it would be expected that ibuprofen formulated at pH 5 would be more permeable than formulations at pH 7.4. However, this did not correspond to the results (membrane studies) obtained in this study. It may be attributed to the solubility of ibuprofen in the different formulations. According to the pH-solubility profile of ibuprofen obtained in this study, it was more soluble at pH 7.4 than at pH 5. This was due to the fact that ibuprofen is a weak acidic compound, and for every 3 units away from the pKa-value, the solubility changes 10-fold (Mahato, 2007:14). However, with regard to the skin permeation studies, enhanced permeation was obtained with the formulations prepared at pH 5. This was in accordance with Corrigan et al., (2003:148) who stated that NSAIDs are less soluble and more permeable at low pH values, and more soluble and less permeable at high pH values. This was most probably due to the fact that unionised species, although possessing a lower aqueous solubility than the ionised species, resulted in enhanced skin permeation due to being more lipid-soluble. Finally, stability tests on the different semi-solid formulations for a period of three months at different temperature and humidity conditions were conducted to determine product stability. The formulations were stored at 25 °C/60% RH (relative humidity), 30 °C/60% RH and 40 °C/75% RH. Stability tests included: mass variation, pH, zeta potential, droplet size, visual appearance, assay, and viscosity. No significant change was observed for mass variation, pH, zeta potential and droplet size over the three months for any of the different formulations stored at the different storage conditions. In addition, no significant change in colour was observed for the gel and emulgel formulations at pH 5 and 7.4 over the three months at all the storage conditions. However, it was observed that the formulations containing Pheroid™ showed a drastic change in colour at all the storage conditions. This might have been due to oxidation of certain components present in the Pheroid™ system. Consequently, further investigation is necessary to find the cause of the discolouration and a method to prevent it. The gel formulated at pH 5 depicted the formation of crystals. This might have been due to the fact that the solubility of ibuprofen was exceeded, leading to it precipitating from the formulation. A possible contributing factor to the varying assay values obtained during the study might have been due to non-homogenous sample withdrawal. On the other hand, no significant change was observed for the emulgel and Pheroid™ emulgel formulated at pH 5 and 7.4. The emulgel and Pheroid™ emulgel formulated at pH 5 depicted relative instability (according to the International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use, ICH) only at 40 °C/75% RH with a change in ibuprofen content of more than 5% (6.78 and 6.46%, respectively). The gel, emulgel and Pheroid™ emulgel at pH 7.4 exhibited the least variation in ibuprofen concentration at all of the storage conditions. This might indicate that the pH at which a semi-solid formulation is produced will have a direct influence on the stability of the product. No significant changes in viscosity (%RSD < 5) was observed for the gel and emulgel formulated at pH 7.4 and stored at 25 °C/60% RH. The remaining formulations at all of the specified storage conditions exhibited a significant change in viscosity (%RSD > 5) with a decrease in viscosity being more pronounced at the higher temperature and humidity storage conditions. A possible contributing factor to the change in viscosity over three months at the specified storage conditions might have been due to the use of Pluronic® F-127 (viscosity enhancer). This viscosity enhancer possesses a melting point of approximately 56 °C (BAST Corporation. s.a). The problem with this might have been the temperature (70 °C) at which the formulations were prepared. The higher preparation temperature might have caused the Pluronic® F-127 to degrade, thereby losing its ability to function appropriately. A balance must be maintained between optimum solubility and maximum stability (Pefile & Smith, 1997:148). Despite the lower skin permeation of the gel formulated at pH 7.4, this formulation performed the best, as it was considered stable (least variation during the 3 month stability test) and the obtained tape stripping results showed that this formulation depicted the highest ibuprofen concentrations in the stratum corneum and epidermis. Thus, topical as well as transdermal delivery were obtained. / Thesis (MSc (Pharmaceutics))--North-West University, Potchefstroom Campus, 2013.

Emulsions are widely used as topical formulations in the pharmaceutical and cosmetic industry. They are thermodynamically unstable and require emulsifiers to stabilize them physically. A literature survey has revealed that emulsifiers could have an effect on topical delivery. Therefore, the overall aim of this research project was to investigate and to understand the various effects of biopolymers, chosen for this study as emulsifiers, on the release and the topical delivery of an active ingredient from emulsion-based delivery systems. Emulsions were stabilized by either whey protein alone or in combination with chitosan or carrageenan. Salicylic acid was chosen as a model drug. Furthermore, the emulsions were prepared at three different pH values (pH 4, 5 and 6) in order to introduce different charges to the polymeric emulsifiers and subsequently determine the effect of pH on release as well as on dermal and transdermal delivery. Emulsion characteristics, such as droplet size, zeta potential, viscosity and stability against creaming and coalescence were ascertained. In addition, turbidity was determined to evaluate the degree of insoluble complex formation in the aqueous phase of the emulsions. A high pressure liquid chromatographic (HPLC) method was validated for the quantitative determination of salicylic acid in the release, skin and transdermal perfusate samples. Nine emulsions were formulated, utilizing the layer-by-layer (LbL) self-assembly technique, from which the release of salicylic acid was determined. These release studies were conducted, utilizing nitrocellulose membranes (0.2 μm pore size) with the use of Franz-type diffusion cells in four replicates per formulation over a time period of 8 hours. Based on the emulsion characterization and release data, six formulations, including the oil solution, were chosen to determine dermal and transdermal delivery of salicylic acid. During the diffusion studies, the effect of different pH (whey protein pH 4.00, 5.00 and 6.00), different polymers and different polymer combinations were investigated. These diffusion studies were conducted with the use of dermatomed (thickness ~400 μm), human abdominal skin and Franz-type diffusion cells over a period of 24 hours. The characterization of the emulsions revealed no significant differences in the droplet size and viscosity between the various formulations. All emulsions showed stability towards coalescence over a time period of 7 days; however, not all the emulsions showed stability towards creaming and flocculation. The results of the release studies indicated that an increase in emulsion droplet charge could have a negative effect on the release of salicylic acid from these formulations. In contrast, positively charged emulsion droplets could enhance the dermal and transdermal delivery of salicylic acid from emulsions. It was hypothesized that electrostatic complex formation between the emulsifier and salicylic acid could affect the release, whereas electrostatic interaction between emulsion droplets and skin could influence dermal/transdermal delivery of the active. Furthermore, the degree of ionization of salicylic acid played an important role in the dermal and transdermal delivery of salicylic acid from the various emulsions. / MSc (Pharmaceutics), North-West University, Potchefstroom Campus, 2014

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmaceutical Technology Candidate: Pavel Hladký Consultant: PharmDr. Barbora Švecová, Ph.D. Title of Thesis: Formulation and (trans)dermal application of imiquimod Imiquimod (IMQ) is an active pharmaceutical substance which belongs to the group of heterocyclic imidazoquinolines. The mechanism of its effect is an induction of cellular immune response after topical administration, that is used for a treatment of tumors or viral diseases of the skin. In the Czech Republic it is available like a cream called Aldara® , the content of IMQ is 5 %. Although Aldara® is an effective medicine, many problems are associated with its use, especially high price, undesirable effects, disposable use, environmental pollution, etc. The aim of this work was to prepare new liposomes for topical administration containing lower ammount of IMQ (0.5 %) and evaluation of penetration of IMQ into human skin in vitro. To improve the entrance of the drug into the skin transdermal penetration enhancers were used. Permeation experiments were performed in Franz diffusion cells on human skin under conditions as close as possible to the physiological environment of the organism. Subsequently, the individual layers of the skin (stratum corneum, the epidermis,...

Background: The buprenorphine transdermal system (BTDS) is approved in the US for the management of chronic pain. Due to its high affinity for mu-opioid receptors with a slow dissociation profile, buprenorphine may potentially displace or prevent the binding of competing mu-opioid-receptor agonists, including immediate-release (IR) opioids, in a dose-dependent manner. Health care professionals may assume that the use of IR opioids for supplemental analgesia during BTDS therapy is not acceptable. Materials and methods: This post hoc analysis evaluated the use of IR opioids as supplemental analgesia during the management of moderate-severe chronic pain with BTDS at 52 US sites (BUP3015S, NCT01125917). Patients were categorized into IR-opioid and no-IR-opioid groups. At each visit of the extension phase, adverse events, concomitant medications, and information from the Brief Pain Inventory (BPI) were recorded. Results: The most common supplemental IR opioids prescribed during BTDS treatment (n=354) were hydrocodone-acetaminophen and oxycodone-acetaminophen. The mean daily dose of IR opioids (morphine equivalents) for supplemental analgesia was 22 mg. At baseline, BPI pain intensity and BPI - interference scores were higher for patients in the IR-opioid group. In both treatment groups, scores improved by week 4, and then were maintained throughout 6 months of the open-label extension trial. The incidence of treatment-emergent adverse events was similar in both groups. Conclusion: Patients who were prescribed IR opioids reported lower scores for BPI pain intensity and pain interference to levels similar to patients receiving BTDS without IR opioids, without increasing the rate or severity of treatment-emergent adverse events. Patients prescribed concomitant use of IR opioids with BTDS had greater treatment persistence. The results of this post hoc analysis provide support for the concomitant use of IR opioids for supplemental analgesia during the management of moderate-severe chronic pain with BTDS.

Currently, clinical trials in patients are required by most regulatory authorities for the assessment of bioequivalence of topical products where the drug is not intended for systemic absorption. Hence there is a dire need for suitable methods for the assessment of bioavailability and bioequivalence of such products since clinical safety and efficacy studies are expensive, time-consuming and require very large numbers of patients. Except for topical corticosteroid products where the human skin blanching assay/vasoconstrictor assay has been approved by the US FDA for bioequivalence assessment of those products, no other method has been “officially” approved for use in those investigations. However, a few alternative methods such as tape stripping and microdialysis have been pursued and considered to have the potential for use in ioequivalence/bioavailability studies. The human skin blanching assay was used to assess the bioequivalence of commercially available topical products containing 0.05% clobetasol propionate. Both visual and chromameter data were obtained and a commercially available topical corticosteroid product, Dermovate® cream was used as both the “Test” and the “Reference” product. The results indicated that both visual and chromametric assessments were comparable to each other and that either could be used for the assessment of the bioequivalence of topical products containing clobetasol propionate. The screening procedure was optimized to identify potential “detectors” for inclusion in the bioequivalence studies. This resulted in fewer subjects being required in a bioequivalence pivotal study, still having the necessary power to confirm bioequivalence using the human skin blanching assay. Another objective of this research was to re-visit tape stripping and other possible alternative methods such as dermal microdialysis and to optimize these procedures for bioequivalence assessment of topical formulations where the drug is not intended for systemic absorption. In the past few decades, tape stripping has been used to investigate bioavailability/bioequivalence of various topical formulations. This technique involves the removal of the stratum corneum to assess drug penetration through the skin. A draft FDA guidance for tape stripping was initially published but was subsequently withdrawn due to high variability and poor reproducibility. This research project used an optimized tape stripping procedure to determine bioavailability and establish bioequivalence between three commercially available formulations containing 0.05 % m/m clobetasol propionate. Furthermore, tape stripping was validated by undertaking a study to assess the bioequivalence of a 0.05% topical cream formulation (Dermovate® cream) using the same cream as both the “Test” and “Reference” product, in which bioequivalence was confirmed. The findings highlight the potential of tape stripping as an alternative method for the assessment of bioequivalence of clobetasol propionate formulations and may possibly be extended for use in other topical products. Microdialysis is another useful technique that can assess the penetration of topically applied substances which diffuses through the stratum corneum and into the dermis. Microdialysis has previously been successfully used for in vivo bioavailability and bioequivalence assessments of topical formulations. However, the drugs which were under investigation were all hydrophilic in nature. A major problem with the use of microdialysis for the assessment of lipophilic substances is the binding/adherence of the substance to the membrane and other components of the microdialysis system. As a result, this necessitates the development of a microdialysis system which can be used to assess lipophilic drugs. Intralipid® 20% was investigated and successfully utilized as a perfusate to recover a lipophilic topical corticosteroid, clobetasol propionate, in microdialysis studies. Hence, the bioavailability of clobetasol propionate from an extemporaneous preparation was determined in healthy human volunteers using microdialysis. These findings indicate that in vivo microdialysis can be used to assess lipophilic drug penetration through the skin. A novel approach to investigate drug release from topical formulations containing 0.05% clobetasol propionate using in vitro microdialysis was also undertaken. The in vitro findings were found to be in agreement with the results obtained using tape stripping to assess bioequivalence of the same commercially available products, namely Dermovate® cream, Dovate® Cream and Dermovate® ointment. These results indicate the potential to correlate in vitro with in vivo data for bioequivalence assessment of such topical dosage forms.

A incidência de casos de melanoma tem aumentado em todo o mundo sendo que, apesar do diagnóstico precoce e do advento das terapias moleculares, o número de pacientes que morrem com a doença em estágio avançado continua em elevação. Deste modo as pesquisas atuais têm focado no desenvolvimento de diferentes estratégias para a disponibilização de terapias eficazes e acessíveis. Nesse contexto, a via de administração transdérmica constitui uma alternativa promissora para aumentar a eficácia local e sistêmica de fármacos, incluindo agentes antitumorais. Diversos métodos têm sido desenvolvidos para maximizar a permeação cutânea de fármacos, destacando-se, entre esses, a ablação térmica por radiofrequência (RF). Esse processo resulta na criação de vários microcanais entre a epiderme e a derme, pelos quais diversas moléculas podem passar em direção às camadas mais profundas da pele. Nesse estudo, a eficácia da infusão transdérmica de etoposídeo por dispositivo de radiofrequência fracionada foi avaliada em modelo de melanoma murino. Camundongos da linhagem C56BL/6 foram divididos nos seguintes grupos experimentais: 1) controle; 2) tratados com radiofrequência; 3) tratados com a aplicação tópica de etoposídeo; e 4) tratados com radiofrequência e posterior aplicação tópica de etoposídeo. Os tratamentos foram realizados durante o período de 28 dias. O peso corpóreo, o volume tumoral e o perfil hematológico foram avaliados semanalmente. Ao término do tratamento os animais foram eutanasiados e procedeu-se a coleta da massa tumoral e dos órgãos (pulmão, baço, rins, linfonodos e fígado) para análise histopatológica. As células tumorais obtidas das massas tumorais foram analisadas quanto às alterações do ciclo celular e do potencial transmembrânico mitocondrial. Os resultados demonstraram que o tratamento com etoposídeo isolado reduziu a sobrevida dos animais e ocasionou alterações histológicas indicativas de toxicidade. Em contrapartida, a infusão transdérmica do etoposídeo por dispositivo de radiofrequência promoveu redução significativa do volume tumoral, em comparação com todos os grupos experimentais, sem ocasionar mortalidade. Esse tratamento também diminuiu a plaquetocitose e elevou o número de eritrócitos em comparação com os outros grupos. A análise histopatológica dos órgãos dos animais tratados com RF + etoposídeo evidenciou que não houveram alterações significativas na arquitetura tecidual. Ainda, o grupo tratado com RF + etoposídeo foi o que apresentou o maior percentual de células estacionadas na fase S/G2M e com mitocôndrias inativas, evidenciando o aumento da eficácia demonstrada no estudo in vivo. O conjunto de resultados sugere que o tratamento com a radiofrequência seguida do etoposídeo resulta em melhor resposta antitumoral do quimioterápico, com baixos índices de toxicidade sistêmica / The incidence of melanoma cases has increased worldwide and, despite early diagnosis and targeted molecular therapy, the number of patients dying from metastatic disease continues to rise. Thus, current research has focused on the development of different treatment strategies to provide efficient and accessible solutions. In this sense, transdermal delivery is a promising alternative enhancing the local and systemic efficacy of drugs, including antitumor agents. Several methods have been developed to improve the skin permeation of drugs, highlighting, among those, the radiofrequency thermal ablation (RFA). This process results in the creation of many microchannels between the epidermis and the dermis through which several molecules can pass towards the deeper layers of the skin. In this study, the efficacy of the transdermal delivery of etoposide by a fractional radiofrequency device was evaluated in a murine melanoma model. C56BL/6 lineage mice were divided into the following experimental groups: 1) control; 2) treated with radiofrequency; 3) treated with topical applications of etoposide; and 4) treated with radiofrequency followed by topical applications of etoposide. The animals were treated for 28 days and the body weight, tumor volume and hematological profile were analyzed weekly. At the end of the treatments, the animals were euthanized and the tumor mass and organs (lung, spleen, kidneys, lymph nodes and liver) were collected for histopathological analysis. Tumor cells obtained from the tumor masses were analyzed for changes in the cell cycle and mitochondrial transmembrane potential. The results showed that the treatment with etoposide alone reduced the survival of the animals and caused histological changes indicating toxicity. On the other hand, the transdermal delivery of etoposide by a radiofrequency device resulted in a significant reduction of the tumor volume, in comparison with all the experimental groups, not causing mortality. This treatment also decreased thrombocytosis and increased the number of red blood cells compared to the other groups. The histopathological analysis of the organs from animals treated with RFA + etoposide demonstrated that there was no significant change in tissue architecture. Furthermore, the group treated with RFA + etoposide presented the highest percentage of cells with inactive mitochondria and interruption at the S/G2M stage, corroborating the increased efficacy of the in vivo study. The set of results indicates that the treatment with radiofrequency followed by etoposide results in better antitumor responses of chemotherapy, with low toxicity rates

Nous proposons dans le cadre de ce travail de thèse, une nouvelle approche de la détection non invasive de l’alcoolémie sanguine à l’aide de microcapteurs d’éthanol à base de SnO2. Cette méthodologie se base sur une détection indirecte de l’alcoolémie sanguine par une mesure des vapeurs d’éthanol émises par la perspiration cutanée suite à une consommation d’alcool. Afin de valider cette approche, il a fallu dans un premier temps démontrer la pertinence et la faisabilité de cette méthodologie de détection par la réalisation d’essais cliniques pilotes en collaboration avec une équipe médicale d’étude pharmacologique du CPCET Marseille. Les différentes mesures du taux d’éthanol réalisées dans les fluides biologiques tels que le sang et l’air expiré ont pu être précisément corrélées avec les mesures de vapeurs d’éthanol réalisées à travers la perspiration à l’aide de trois microcapteurs de gaz commerciaux à base d’oxydes métalliques intégrés à un bracelet. Ces dispositifs ont l’avantage d’être sensibles mais pas sélectifs à la nature du gaz détecté. Durant ces travaux, des couches sensibles de SnO2 ont été déposées par pulvérisation cathodique RF magnétron réactive sur un transducteur breveté par notre équipe, intégrant trois capteurs sur une même puce. L’optimisation des paramètres de dépôt et les analyses structurales des couches de SnO2, nous ont permis de réaliser un multicapteur d’éthanol démontrant des performances sous éthanol ; en termes de sensibilité sous atmosphère humide, de répétabilité et de temps de réponses et de recouvrement ainsi que du point de vue sélectivité / A new approach of a noninvasive detection of blood alcohol concentration using ethanol microsensors based on SnO2 Is developed in this work. The methodology is based on an indirect detection of blood alcohol concentration by measuring the ethanol vapor emitted through the skin perspiration after alcohol consumption. In order to validate this approach, first we demonstrated the relevance and the feasibility of this detection method by carrying out pilot clinical trials in collaboration with a medical team of pharmacological study of CPCET Marseille. The different measurements of the ethanol concentration carried out in biological fluids such as blood and exhaled air could be precisely correlated with the measurements of ethanol vapors performed through the perspiration using three commercial gas microsensors based on metal oxides integrated into a bracelet. . These devices have the advantage of being sensitive but not selective to the nature of the gas detected. During this thesis work, sensitive layers of SnO2 were deposited by reactive magnetron RF sputtering on a transducer patented by our team, integrating three sensors on the same chip. The optimization of the deposition parameters and the structural analyzes of the SnO2 layers, allowed us to develop an ethanol multi-sensor demonstrating performances under ethanol; in terms of sensitivity on humidity, repeatability and response and recovery times as well as from the point of selectivity